Cargando…
Palladium-Mediated Dealkylation of N-Propargyl-Floxuridine as a Bioorthogonal Oxygen-Independent Prodrug Strategy
Herein we report the development and biological screening of a bioorthogonal palladium-labile prodrug of the nucleoside analogue floxuridine, a potent antineoplastic drug used in the clinic to treat advanced cancers. N-propargylation of the N3 position of its uracil ring resulted in a vast reduction...
Autores principales: | Weiss, Jason T., Carragher, Neil O., Unciti-Broceta, Asier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365405/ https://www.ncbi.nlm.nih.gov/pubmed/25788464 http://dx.doi.org/10.1038/srep09329 |
Ejemplares similares
-
Extracellular palladium-catalysed dealkylation of 5-fluoro-1-propargyl-uracil as a bioorthogonally activated prodrug approach
por: Weiss, Jason T., et al.
Publicado: (2014) -
Development and Bioorthogonal Activation of Palladium-Labile
Prodrugs of Gemcitabine
por: Weiss, Jason T., et al.
Publicado: (2014) -
N-alkynyl derivatives of 5-fluorouracil: susceptibility to palladium-mediated dealkylation and toxigenicity in cancer cell culture
por: Weiss, Jason T., et al.
Publicado: (2014) -
Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium‐Functionalized Microdevices
por: Adam, Catherine, et al.
Publicado: (2018) -
Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis
por: Sancho-Albero, María, et al.
Publicado: (2019)